Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajay Hooda

Hospitalist Baltimore, MD Medical Doctor

NPI 1649414921 CMS profile 74486

2401 W Belvedere Ave, 5Th Floor - Hospitalist, Baltimore, MD 21215

Open in the dashboard

General payments

$5,382

268 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ajay Hooda of Baltimore, MD is reported in the CMS Open Payments database as having received $5,382 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $484 19
2024 General $743 35
2023 General $1,122 53
2022 General $1,021 54
2021 General $1,089 55
2020 General $382 24
2019 General $540 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajay Hooda
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Ajay Hooda were reported at $484. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Ajay Hooda Hospitalist median Middle half National median
2019 $540 $96 $28–$201 $163
2020 $382 $48 $19–$125 $114
2021 $1,089 $70 $23–$167 $132
2022 $1,021 $85 $27–$174 $149
2023 $1,122 $89 $30–$191 $160
2024 $743 $95 $29–$204 $164
2025 $484 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,278 69 payments
  2. E.R. Squibb & Sons, L.L.C. $1,064 61 payments
  3. Pfizer Inc. $469 21 payments
  4. AbbVie, Inc. $444 19 payments
  5. Novartis Pharmaceuticals Corporation $378 20 payments
  6. Alexion Pharmaceuticals, Inc. $376 14 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $229 10 payments
  8. Gilead Sciences, Inc. $142 7 payments
  9. Allergan Inc. $137 7 payments
  10. Merck Sharp & Dohme Corporation $122 7 payments
  11. Other $744 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,382 268 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,278 69 payments
  2. ELIQUIS Cardiovascular $857 51 payments
  3. ELIQUIS Cardiovascular;Metabolic Disease $429 19 payments
  4. DALVANCE $371 16 payments
  5. TEFLARO $253 12 payments
  6. ENTRESTO $231 13 payments
  7. XIFAXAN $229 10 payments
  8. CAMZYOS $171 8 payments
  9. Soliris $169 6 payments
  10. LEQVIO $147 7 payments
  11. Other $1,707 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$1,895

Medicare's payments for the services billed

Medicare patients

20

Average age 75

Services billed

26

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Diabetes 65%
Depression 60%
Chronic kidney disease 55%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $186
$186 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $113
$113 — —
DALVANCE
  • AbbVie, Inc. $50
$50 — —
Wegovy
  • Novo Nordisk Inc $44
$44 — —
DIFICID
  • Merck Sharp & Dohme Corporation $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospitalist in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record